Karma

Karma Biotechnologies is a preclinical-stage biotechnology company focused on developing tolerogenic vaccines to treat autoimmune diseases, allergies, and inflammatory conditions. The company's proprietary X-TOL platform is designed to induce antigen-specific immune tolerance, effectively retraining the immune system to stop attacking healthy tissues or harmless substances. This approach aims to provide long-lasting therapeutic effects without the side effects associated with broad immunosuppression. Karma's current pipeline includes programs targeting Type 1 diabetes, multiple sclerosis, and the prevention of anti-drug antibodies in hemophilia A. By leveraging a modular design, the X-TOL technology can be rapidly adapted to a wide variety of immune-mediated disorders. The company is headquartered in Torrance, California, and has received backing from prominent investors including Y Combinator.